PET reveals patient responses to new Alzheimer’s disease drug
AuntMinnie
OCTOBER 27, 2023
Patients with less tau pathology on PET scans may respond better to treatment with the new Alzheimer’s disease drug donanemab, according to an October 25 news report in the journal Practical Neurology. Researchers from donanemab developer Eli Lilly presented a follow-up analysis of data from the TRAILBLAZER-ALZ 2 clinical trial at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 conference in Boston.
Let's personalize your content